Anika Therapeutics | ANIK - Cost Of Sales


Anika Therapeutics reported $11.44M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Abbott USD 5.94B 642M Jun/2026
Agenus USD 642K 399K Sep/2025
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Anika Therapeutics USD 11.44M 797K Dec/2025
Halozyme Therapeutics USD 108.68M 67K Jun/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Insmed USD 69.29M 19.79M Jun/2026
Integra LifeSciences USD 188.86M 10.15M Jun/2026
Intrexon USD 1.01M 344K Jun/2024
J&J USD 8B 67M Jun/2026
Karyopharm Therapeutics USD 1.34M 139K Mar/2026
Ligand Pharmaceuticals USD 11.31M 59K Jun/2026
MacroGenics USD 9.53M 585K Mar/2026
Merit Medical Systems USD 203.68M 6.6M Jun/2026
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sanofi EUR 3.02B 656M Jun/2026
Smith & Nephew USD 901M 31M Jun/2026
Stryker USD 2.26B 106M Jun/2026
Veracyte USD 42.19M 3.7M Jun/2026
Xencor USD 61.66M 50.95M Jun/2025
Zimmer Biomet Holdings USD 815.9M 77.6M Jun/2026